Mandeep K Sekhon
YOU?
Author Swipe
View article: The impact of CMV reactivation on mortality after chimeric antigen receptor T-cell therapy
The impact of CMV reactivation on mortality after chimeric antigen receptor T-cell therapy Open
View article: Off-the-shelf allogeneic natural killer cells for the treatment of COVID-19
Off-the-shelf allogeneic natural killer cells for the treatment of COVID-19 Open
View article: Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients
Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients Open
Human herpesvirus 6B (HHV-6B) reactivation and disease are increasingly reported after chimeric antigen receptor (CAR) T-cell therapy (CARTx). HHV-6 reactivation in the CAR T-cell product was recently reported, raising questions about prod…
View article: Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy
Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy Open
Background The epidemiology of cytomegalovirus (CMV) after chimeric antigen receptor–modified T-cell immunotherapy (CARTx) is poorly understood owing to a lack of routine surveillance. Methods We prospectively enrolled 72 adult CMV-seropos…